20 March 2025 - Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada.

Hikma Pharmaceuticals announces the approval of Kloxxado (naloxone hydrochloride) 8 mg nasal spray by Health Canada for the treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult patients.

Read Hikma Pharmaceuticals press release